SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy

GERMANTOWN, Md., Nov. 12, 2018 /PRNewswire/ -- SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.

An analysis of islet transplant trials registered on clinicaltrials.gov was conducted with the goal of extracting insights to apply in the study design of SERAXIS lead candidate, SR-01 for the treatment of type 1 diabetes. The results of this analysis were published this week in Stem Cells Translational Medicine (doi:10.1002/sctm.18-0156). SR-01 is a combination therapy of insulin-producing cells encapsulated in the retrievable biocompatible SeraGraft^TM device, designed to prevent immune system access to the cells after implantation. The SeraGraft ^TM device has been shown to protect encapsulated cells in immune-competent diabetic models, to facilitate rapid vascularization of the graft without inducing a fibrotic response. If successful, SR-01 cell replacement therapy has the potential to provide a novel therapeutic modality to insulin-dependent type 1 diabetes patients, and SERAXIS is establishing a strategic relationship with a major clinical transplant program toward that end. The SERAXIS therapy could overcome some of the challenges associated with current pancreatic islet transplant protocols, providing a theoretically unlimited supply of insulin-producing cells and reducing or eliminating the need for post-transplant pharmacologic immunosuppression.

About SERAXIS INC.

SERAXIS is a privately held biotechnology company, incorporated in Singapore and the United States. SERAXIS used proprietary technologies to develop: (1) a cell therapy that functions shortly after transplantation in diabetic animals and; (2) a device, SeraGraft ^TM that safely protects these human pancreas cells from the immune system of animal hosts without need for pharmacologic immunosuppression. Further information can be found at www.seraxis.com

SOURCE SERAXIS Inc.